Cover Image
市場調查報告書

極光激酶B:開發中產品分析

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365762
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
極光激酶B:開發中產品分析 Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 64 Pages
簡介

本報告提供以極光激酶B為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

極光激酶B 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AbbVie Inc.
  • Advenchen Laboratories, LLC
  • Aeterna Zentaris Inc.
  • Amgen Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Chipscreen Biosciences Ltd
  • Merck KGaA
  • Nemucore Medical Innovations, Inc.
  • Sanofi
  • Sareum Holdings Plc
  • Vertex Pharmaceuticals Incorporated
  • Vichem Chemie Research Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0996TDB

Title:
Aurora Kinase B
(Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Pipeline Review, H2 2017.

Summary:

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Aurora Kinase B - Pipeline Review, H2 2017, outlays comprehensive information on the Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Aurora B kinase is a protein that functions in the attachment of the mitotic spindle to the centromere. It is involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. It is required for central spindle assembly and cleavage furrow formation. It plays an important role in cytokinesis checkpoint. Phosphorylation of INCENP leads to increased AURKB activity. Other AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, GSG2/Haspin, and histone H3. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 3, 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Gastric Cancer, Liver Cancer, Myelodysplastic Syndrome, Neuroblastoma, Renal Cell Carcinoma, Small-Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Breast Cancer, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia and Relapsed Acute Myeloid Leukemia.

Furthermore, this report also reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1)
  • The report reviews Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Overview
    • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Advenchen Laboratories LLC
    • Aeterna Zentaris Inc
    • Amgen Inc
    • AstraZeneca Plc
    • Chipscreen Biosciences Ltd
    • Cielo Therapeutics Inc
    • Sanofi
    • Sareum Holdings Plc
  • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Drug Profiles
    • AL-8326 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-2811 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-2164 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • danusertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ilorasertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NMI-900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-156497 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Aurora A/B Kinase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Aurora B Kinase and ERK2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TY-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Dormant Products
  • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Discontinued Products
  • Aurora Kinase B (Aurora 1 or Aurora And IPL1 Like Midbody Associated Protein 1 or Serine/Threonine Protein Kinase 12 or Serine/Threonine Protein Kinase 5 or Serine/Threonine Protein Kinase Aurora B or STK1 or AURKB or EC 2.7.11.1) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 03, 2016: China and Hong Kong Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors
      • May 10, 2016: Data Published in Journal of Controlled Release Demonstrate Flexibility of ACCURINS to Encapsulate a Broad Range of Physically and Chemically Diverse Payloads with High Encapsulation Efficiency and Tunable Release Kinetics
      • Feb 10, 2016: AZD2811 ACCURINS Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies
      • Nov 18, 2015: BIND Therapeutics Announces Initiation of Clinical Studies with Accurin AZD2811 in Solid Tumors
      • Sep 15, 2015: US and European Patent Grants for Sareum's Aurora+FLT3 Kinase Inhibitors
      • Jun 23, 2015: BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811
      • Apr 22, 2015: BIND Therapeutics Presents Data Highlighting Ability of Accurin drug candidate AZD2811 to Accumulate in Target Tissue at AACR Annual Meeting 2015
      • Mar 18, 2015: Data from Abstracts Validating Potential of BIND Therapeutics AZD2811 to be Presented at American Association for Cancer Research Annual Meeting
      • Mar 05, 2014: BIND Therapeutics to Present Data on Barasertib at the AACR 2014 Annual Meeting
      • Jul 15, 2013: Preclinical Development Candidate Selected for Aurora+FLT3 Inhibitor Programme
      • Sep 03, 2012: Chipscreen filed a new IND application on a novel dual-pathway targeted inhibitor Chiauranib to SFDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by AbbVie Inc, H2 2017
  • Pipeline by Advenchen Laboratories LLC, H2 2017
  • Pipeline by Aeterna Zentaris Inc, H2 2017
  • Pipeline by Amgen Inc, H2 2017
  • Pipeline by AstraZeneca Plc, H2 2017
  • Pipeline by Chipscreen Biosciences Ltd, H2 2017
  • Pipeline by Cielo Therapeutics Inc, H2 2017
  • Pipeline by Sanofi, H2 2017
  • Pipeline by Sareum Holdings Plc, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Dormant Products, H2 2017 (Contd..3), H2 2017
  • Discontinued Products, H2 2017
  • Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top